How Does the Tumor ‘Turn Off’ Immune Switches?
July 8, 2026Core Framework & Diagram How Does the Tumor Transform Immune Cells?
July 9, 2026
How Does the Tumor Transform Immune Cells?
Tumors don't just 'suppress' immune cells — they turn guards into accomplices
By the Editors 1-min read
Imagine this scenario: a city is occupied, and the enemy doesn't eliminate all the police — instead they 'co-opt' some of them. People who originally protected the city now help maintain the occupation order. This is exactly what tumors do to immune cells: macrophages are polarized into M2 type, no longer killing tumors but secreting tumor-growth-promoting factors; T cells enter exhaustion, becoming 'present but ineffective' shells; dendritic cells are 'anesthetized,' unable to effectively activate new T cell attacks; Tregs are massively recruited, actively suppressing other immune cells' function.
This 'identity hijacking' is more dangerous than simple suppression — because hijacked immune cells don't just stop resisting, they actively help the tumor grow, spread, and escape.
KEY TAKEAWAYS
01
Tumors don't just suppress immune cells — they 'identity hijack': through epigenetic rewriting and sustained signal remodeling, they transform macrophages, DCs, T cells, and Tregs entering TME into 'insiders' protecting and supporting the tumor.
02
M2-TAMs are the most important hijacked immune cells: in some tumors comprising over fifty percent of tumor volume; simultaneously secreting VEGF (angiogenesis), MMP (invasion), IL-10/TGF-β (immune suppression). CSF-1R inhibitors, CD40 agonists, local IL-12 are three main TAM repolarization strategies.
03
DC 'anesthesia' is the critical breakpoint in CTL response: tumor secretes VEGF/IL-10/PGE2 blocking DC maturation, inducing tolerogenic DCs (tDCs). tDCs don't just fail to activate T cells — they actively convert T cells into Tregs or anergy; personalized neoantigen vaccines bypass DC anesthesia.
04
T cell exhaustion's core is epigenetic rewriting: TOX transcription factor under chronic antigen exposure 'locks' exhaustion state; deeply exhausted T cells still limited in function recovery even after PD-1 brake release — HDAC/EZH2 inhibitors combined with checkpoint inhibitors are the direction.
05
Treg accumulation in TME via dual mechanism (CCL22 recruiting peripheral nTregs + TGF-β inducing local iTregs) forms a powerful immunosuppressive network. The biggest challenge in targeting Tregs is avoiding systemic autoimmunity — requires TME-selective targeting strategies (like anti-CCR4, anti-TIGIT).
Art 79
How Does the Tumor Exploit Stress Signals?
→
Art 80
Future Directions in Tumor Immunology
→
